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Thecommoncoldisoneofthemostfrequentillnessescausedbyviralinfection.Recently,wehavereportedthatoraladministration
of cystine and theanine (CT) to mice enhanced the humoral immune response associated with antibody production. Based on this
mouse study, we investigated the eﬀects of CT supplementation on the common cold in humans as a pilot study. A total of 176
healthy male volunteers were randomized to receive either placebo or CT (490mg) tablets twice daily for 35 days. The incidence
outcome was assessed using the deﬁnition in our laboratory based on questionnaires regarding cold symptoms. The incidence of
subjects with colds during the trial was signiﬁcantly lower in the CT group than in the placebo group, although the duration of
the colds was not signiﬁcantly diﬀerent between the groups. These results suggest that CT supplementation may be useful for the
prevention of the common cold.
1.Introduction
The common cold, an acute infection properly known as
“cold syndrome,” is the most common human illness. The
majority of cases of cold syndrome are acute infections of
the upper respiratory tract, and its major cause is viral
infection. From 30 to 50% of cases of cold syndrome
are caused by rhinoviruses, and 10 to 15% are caused by
coronaviruses [1]. Conventional methods of treatment use
medications, such as analgesic agents and antihistamines,
but these are only eﬀective for the alleviation of symptoms,
such as sneezing and runny nose [2]. Furthermore, antiviral
agents, such as neuraminidase inhibitors, are believed to
be eﬀective; however, their application is currently limited
to the inﬂuenza virus [1, 3–6]. Recently, Chinese medicine
and dietary supplements have attracted attention as eﬀective
new methods for the treatment and prevention of cold
syndrome [7]; for example, vitamin C; allysine, which is
found in garlic; and the extract of the natural herb Echinacea
[8–10]. However, there have also been reports indicating that
the incidence of cold syndrome is unaﬀected by the above
treatments [11, 12], and thus their eﬀectiveness has yet to be
clearly demonstrated.
In a previous experiment in mice, we revealed that
the oral administration of L-cystine and L-theanine (CT)
reinforced antigen-speciﬁc antibody production after anti-
gen stimulation; these eﬀects were possibly caused by
the reinforcement of glutathione (GSH) synthesis and the
humoral immune response [13]. Based on previous reports,
the objective of this pilot study was to evaluate the eﬀects of
CT against cold syndrome in humans, using a double-blind
comparative study.
2. Methods
2.1.Procedure. Thisrandomized,double-blind,andparallel-
group comparative study with a placebo group as a reference
was performed as a pilot study in accordance with the
Declaration of Helsinki and after obtaining approval from
all members of the Ajinomoto Co., Inc., Institutional Review2 Journal of Amino Acids
Board (IRB), as organized by the executive director, the
director of the quality assurance department, the general
managers of research and development, and the divisional
director of food business on December 17, 2001.
2.2. Subjects. T h es u b j e c t sw e r eh e a l t h ym a l ev o l u n t e e r s( f o r
safety reasons and to avoid individual diﬀerences inﬂuenced
by the estrous cycle) who are employees of Ajinomoto Co.,
Inc., excluding those with a history of or a current liver
or kidney disease as well as those with critical illness who
were not able to be diagnosed by a clinician. The subjects
were randomly allocated into one of two groups using an
allocation table: a group receiving placebo (P) and another
group receiving cystine/theanine (CT). Both groups were
studied at the same time. Before the test, we determined the
number of subjects with allergy symptoms, the number of
smokers, the number of subjects who caught a cold twice or
moreperyear,andthenumberofsubjectslivingwithschool-
aged children, which are the family members most likely
to catch a cold. When the subjects registered for the study,
the investigator and the physician in charge provided the
informed consent form, which was discussed and approved
by the IRB. The content of the study was explained in detail,
and the subjects provided their written voluntary consent.
2.3. Applied Dose. According to the third National Health
and Nutrition Examination Survey that took place in the
USA from 1988 to 1994, the average intake of L-cystine
or L-cysteine from meals and supplements is 1000mg/day.
In males in the 51 to 70-year-old age group, the average
intake among the subjects in the highest 1% of the group
was 2200mg/day [14]. Considering the safety data described
above, the applied dose in the present study was set at
700mg/day for L-cystine to remain within the range of the
average daily intake of L-cystine or L-cysteine. The applied
dose of L-theanine was calculated as 280mg/day based on
analyses in mice, which suggested that the most eﬀective
weight ratio of cystine : theanine = 5:2[ 13]. Glycine was
usedasaplacebosothatthesubjectsreceivedthesamesource
of nitrogen, and the applied dose was set at 980mg/day.
2.4. Study Procedure. During the 5-week period from Jan-
uary 18, 2002 to February 21, 2002, the subjects were asked
to take 2 tablets orally after breakfast and 2 tablets orally
after dinner, with each tablet containing 175mg of L-cystine
plus 70mg of L-theanine or 245mg of glycine as a placebo
(φ11mm, Table 1) (a total of 4 tablets daily; total daily
consumption of cystine, theanine, and glycine = 700mg,
280mg, and 980mg, resp.). Each tablet was manufactured
by Aliment Industry Co., LTD. (Yamanashi, Japan).
T h eo n s e to fc o m m o nc o l ds y m p t o m sa sw e l la sd a t a
regarding intake of the test meals during this 5-week period
were recorded by the subjects on a daily basis as described
below.
The subjects performed a self-evaluation of 19 symptom
items (“symptoms of the common cold”: runny nose, stuﬀy
nose, sneezing, sore throat, cough, sputum, chills, fever,
headache, joint pain, pain in the skin, and general malaise;
Table 1: Components of each tablet.
Cystine/Theanine Placebo
L-Cystine 175 —
L-Theanine 70 —
Glycine — 245
Microcrystalline cellulose 100 100
Dextrin 114 115
Micronized silicon dioxide 2.5 10
Glycerine fatty acid ester 32.5 25
Aspartame 1 —
Vanilla ﬂavor 5 5
Total 500 500
“adverse events accompanying test meal ingestion”: nausea,
vomiting, abdominal pain, diarrhea, loss of appetite, chest
pain, and skin rash) which were graded according to 3
levels (+: presence of symptoms, ±: slight symptoms, and −:
absence of symptoms). Data were recorded, and the subjects’
temperatures were taken under the arm. The subjects were
not restricted with regard to medical treatment during this
period, such as taking medication for the common cold, but
were asked to record any treatment received.
2.5. Data Processing and Statistical Analyses. In the analysis,
the criteria used in the clinical test of anti-inﬂuenza virus
agents were used as a reference [5, 6] because the period
of the trial (January to February) corresponds to the season
in which inﬂuenza virus is most prevalent in Japan. The
symptoms recorded on the data sheets were converted to
scores as follows: presence of symptoms (+) = 2, slight
symptoms (±) = 1, and absence of symptoms (−) = 0.
The items were classiﬁed into four predominant symptoms:
(1) stuﬀy nose/runny nose/sneezing as nasal symptoms, (2)
cough/sputum/sore throat as throat symptoms, (3) chills
and fever as febrile symptoms, and (4) headache/joint
pain/pain in the skin as pain symptoms. If the score for
the predominant symptom was more than 3 of 6 for nasal,
throat, or pain symptoms, the predominant symptom was
considered to be present. We considered febrile symptoms
to be present if the score was more than 2 of 4. If 3 of 4
predominant symptoms were observed on the same day or
if the body temperature was above 37.0
◦C and two or more
c o m m o nc o l ds y m p t o m s( s t u ﬀy nose/runny nose/sneezing,
cough/sputum/sore throat/chills/headache/joint pain/pain
intheskin/generalmalaise)displayedascoreof2,thesubject
w a sc o n s i d e r e dt oh a v et h ec o m m o nc o l d( Table 2). Based
on this deﬁnition, the number of subjects with incidences of
the common cold during the 5-week period of the study was
counted, and the two groups were compared using Fisher’s
exact test. When there was another incidence of the common
cold, according to the above deﬁnition, after 3 or more
days of recovery from an earlier cold, this was counted as
a separate incident. The number of aﬀected days was also
counted and was compared between the two groups using
Poisson regression analysis. In addition, the average duration
of the colds and the number of subjects that experienced aJournal of Amino Acids 3
Table 2: Criteria of laboratory-deﬁned colds.
Incidence of each main symptom
Nasal
Total score/day  3/6 Throat
Pain
Febrile Total score/day  2/4
Incidence of colds
Number of the positive main symptom  3/day
or
Body temperature  37
◦C and number of the cold symptom score
of 2  2/day
body temperature above 37.0
◦C were also determined and
were compared between the two groups using the t-test and
Fisher’s exact test, respectively. The incidences of individual
symptoms of the cold and adverse events in the evaluation of
safety were counted if the score had reached 2 at least once
during the 35-day period of the trial, and the number was
compared between the two groups using Fisher’s exact test.
All statistical analyses were performed using the Statistical
Analysis System (SAS) version 8.2 (SAS Institute, Inc., Cary,
NC, USA), and the results were considered as signiﬁcant at
P<. 05.
3. Results
3.1. Background of the Subjects. The total number of subjects
registered in this study was 176, and, as a result of the
randomized allocation, 89 subjects were allocated into the
CT group and 87 subjects were assigned to the P group.
One subject in the CT group and one subject in the P
group lost their data recording sheets, and one subject in
the P group withdrew the informed consent. Therefore, the
ﬁnal analysis was performed using data from a total of 173
subjects, consisting of 88 subjects in the CT group and 85
subjects in the P group. Table 3 shows the results of the
background factor questionnaire, which was completed by
the subjects prior to the study; there were no signiﬁcant
diﬀerences in background factors between the two groups.
The tablet ingestion rate during the trial period indicates
an approximately 90% ingestion rate in both groups, where
ingestion of 70 tablets during the 5-week trial period was
deﬁned as 100% (Table 4). We counted the number of
subjects in each group according to the ingestion rate, and
there was no signiﬁcant diﬀerence between the two groups
(P = .357).
3.2. Eﬀectiveness. As shown in Figure 1, the incidence of the
common cold in the CT group was lower than in the P
group throughout the 5-week period of the trial. As shown
in Table 5, the incidences of the common cold according to
the deﬁnition set by our laboratory were 11.4% in the CT
group and 27.1% in the P group, with that in the CT group
being signiﬁcantly lower than that in the P group (P = .011).
The cumulative incidences during the trial period were 10
in the CT group and 29 in the P group (in the placebo
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Figure 1: Incidence of laboratory-deﬁned colds on each day during
the 5-week trial period.
group, four subjects had two and one subject had three
separate instances of colds during the trial period); the CT
group demonstrated a signiﬁcantly reduced number of colds
than the P group (P = .002). In addition, the cumulative
numbers of days aﬀected by the common cold were 18 days
in the CT group and 59 days in the P group; the CT group
demonstrated signiﬁcantly fewer days aﬀected by the cold
than the P group (P = .002). The average duration of the
colds was approximately 10% less in the CT group than that
in the P group, although this diﬀerence was not signiﬁcant.
The proportion of subjects with body temperatures above
37
◦C was 18.2% in the CT group and 32.9% in the P group,
with that in the CT group being signiﬁcantly lower than that
in the P group (P = .036). The average duration of a body
temperature above 37
◦C was approximately 15% shorter in
the CT group than in the P group, but the diﬀerence was
not signiﬁcant. In addition, a Poisson regression analysis was
performed to look for correlations between the incidence
of colds and the backgrounds of the subjects as well as
to investigate any interactions between CT ingestion and
the backgrounds of the subjects on the incidence of colds.
However, no signiﬁcant correlations or interactions were
observed between the CT ingestion and the backgrounds of
thesubjectsortheincidenceofcoldsinthepresenttrial(data
not shown).
The results of the analyses regarding the incidences of
each symptom in the trial period are shown in Table 6.F o r
all items except pain in the skin, the incidences of symptoms
were lower in the CT group than in the P group. Chills
and fever in particular, included in the febrile symptoms,
displayed signiﬁcant decreases in incidence in the CT group
(P = .029 and P = .003, resp.). The incidences of
predominant symptoms other than febrile symptoms, such
as runny nose (P = .057), sore throat (P = .089), and joint
pain (P = .069), tended to be lower in the CT group than in
the P group, although the diﬀerences were not statistically
signiﬁcant. The number of times that drugs to treat the4 Journal of Amino Acids
Table 3: Characteristics of the volunteers.
Characteristic Cystine/Theanine group (n = 88) Placebogroup (n = 85) P-value
Age (years; mean ± SE) 39.8 ±1.23 9 .6 ±1.2 .906a
Number of the volunteers
– Allergic predisposition (%) 32 (36.4) 36 (42.4) .440b
– Smokers (%) 22 (25.0) 24 (28.2) .731b
– Colds more than twice per year (%) 57 (64.8) 56 (65.9) 1.000b
– Living with school-age children (%) 30 (34.1) 24 (28.2) .418b
aThe t-test was used for comparisons between groups.
bFisher’s exact test was used for comparisons between groups.
Table 4: Compliance rate of each tablet during the 5-week trial period.
Cystine/Theanine group (n = 88) Placebogroup (n = 85) P-valuea
Level of compliance (%; mean ± SE) 88.5 ±1.79 1 .4 ±1.1—
– Number of volunteers (%)
90∼100% 56 (63.6) 58 (68.2)
70∼90% 23 (26.1) 22 (25.9) .357
<70% 9 (10.2) 5 (5.9)
aCochran-Mantel-Haenszel ANOVA test was used for comparisons between groups.
commoncoldweretakenduringthetrialperiodwas11times
in the CT group and 20 times in the P group (data not
shown).
3.3. Adverse Events. The adverse events accompanying test
meal ingestion were also examined. The incidences of
diarrhea in the CT and P groups were 14.8% and 15.3%,
respectively, which were not signiﬁcantly diﬀerent (Table 7).
No other adverse events related to CT ingestion were
observed.
4. Discussion
The present exploratory trial showed that continuous inges-
tion of CT signiﬁcantly suppressed the incidence of the
common cold compared to a placebo control group and also
signiﬁcantly reduced the incidence of chills and fever among
individual symptoms.
Ikematsu et al. investigated the safety of continuous
ingestion of CoQ10 and asked subjects to self-evaluate
the severity of common cold symptoms on a 4-level scale
[15]. The results indicated that 24 of 85 subjects (28.2%)
experienced incidences of common cold symptoms. By
contrast, in a report on the prevention of upper respiratory
tract infection using extract of North American ginseng
containing poly-furanosyl-pyranosyl-saccharides by Predy
et al., 10 types of common cold symptoms were scored on
a 4-level scale, and the sum of the scores on 2 consecutive
days over 14 was considered as an incidence of the common
cold. In the placebo group, the incidence of colds was 22.8%
during the 4-month trial period [16]. Considering the above
ﬁndings as well as the diﬀerences in weather conditions and
evaluation methods, the 27.1% incidence of colds (P group)
inourstudyindicatedthatthedeﬁnitionofthecommoncold
and the evaluation method used in this study were valid.
Many studies have investigated the eﬀectiveness of vita-
min C in common cold suppression. Limited to those under
physically stressed conditions, a meta-analysis of the eﬀects
of vitamin C indicated 50% suppression of the incidence of
the common cold [17]. In addition, in the above-mentioned
study by Predy et al., ingestion of the ginseng extract was
shown to reduce the incidence of the common cold by
approximately56%[16].Moreover,theextractofthenatural
herbEchinaceawasreportedtohaveaprophylacticeﬃcacyof
55% or 58% on the incidence of common cold by two meta-
analyses [18, 19]. By contrast, a study that employed contin-
uous administration of N-acetylcysteine (NAC) indicated a
43% reduction in the incidence of inﬂuenza-like symptoms
[20]. In the present study, the incidence of the common cold
according to our deﬁnition was decreased by approximately
58% by CT ingestion. This result indicated that CT has a
cold prevention eﬀect with an eﬃcacy similar to that of
other nutrients that are considered to possess this eﬀect. As
previously mentioned, the majority of common colds are
caused by viral infection, with rhinoviruses being the most
common infectious agent [1]. These viruses are known to
infect cells via intercellular adhesion molecule-1 (ICAM-
1), which is a receptor on epithelial cells of the respiratory
tract, and reduced GSH is known to inhibit the increased
expressionofICAM-1[21].Inourpreviousstudyinmice,we
showed that the administration of CT signiﬁcantly increases
theamountofreducedGSH[13].Theaboveﬁndingssuggest
that the increase in reduced GSH due to the ingestion of CT,
which suppressed the expression of the virus receptor, led to
prevention of the common cold and reduced the severity of
cold symptoms.
Theaveragedurationofthecoldswasreducedbyapprox-
imately 10%, although this reduction was not statistically
signiﬁcant. Thirty clinical studies were compared in a
meta-analysisthatwasemployedforthevitaminCstudy,and
it was found that the duration of the colds was reduced byJournal of Amino Acids 5
Table 5: Incidence and duration of laboratory-deﬁned colds during the 5-week trial period.
Cystine/Theanine group (n = 88) Placebo group (n = 85) P-value
Laboratory-deﬁned colds
– Number of volunteers (%) 10 (11.4) 23 (27.1) .011a
– Number of incidence 10 29 .002b
– Cumulative days of incidence 18 59 .002b
– Average duration (mean ± SE) 1.8 ±0.82 .0 ± 1.1 .883c
Temperature,  37.0
◦C
– Number of volunteers (%) 16 (18.2) 28 (32.9) .036a
– Average duration (mean ± SE) 1.7 ±0.22 .0 ± 0.2 .182c
aFisher’s exact test was used for comparisons between groups.
bPoisson regression analysis was used for comparisons between groups.
cThe t-test was used for comparisons between groups.
Table 6: Cold symptoms during the 5-week trial period.
Symptom Cystine/Theaninegroup (n = 88) Placebogroup (n = 85) P-valuea
Nasal
Runny nose 24 (27.3) 35 (41.2) .057
Nasal congestion 19 (21.6) 22 (25.9) .593
Sneeze 16 (18.2) 23 (27.1) .203
Throat
Sore throat 19 (21.6) 29 (34.1) .089
Cough 17 (19.3) 23 (27.1) .280
Sputum 16 (18.2) 19 (22.4) .572
Fever Chill 10 (11.4) 21 (24.7) .029
Fever 9 (10.2) 24 (28.2) .003
Pain
Headache 15 (17.0) 20 (23.5) .345
Arthralgia 7 (8.0) 15 (17.6) .069
Dermatalgia 2 (2.3) 1 (1.2) 1.000
General malaise 13 (14.8) 21 (24.7) .126
aFisher’s exact test was used for comparisons between groups.
Table 7: Adverse events during the 5-week trial period.
Adverse events (%) Cystine/Theaninegroup (n = 88) Placebogroup (n = 85) P-valuea
Nausea 5 (5.7) 6 (7.1) .764
Vomiting 1 (1.1) 4 (4.7) .205
Abdominal pain 8 (9.1) 9 (10.6) .802
Diarrhoea 13 (14.8) 13 (15.3) 1.000
Anorexia 4 (4.5) 8 (9.4) .243
Chest pain 2 (2.3) 0 (0.0) .497
Skin rash 0 (0.0) 0 (0.0) —
aFisher’s exact test was used for comparisons between groups.
8% in adults and 13.6% in children due to the ingestion of
vitamin C [22]. Taking these results into consideration, we
feel that another study of about the same scale or larger than
this study will reveal a clear eﬀect of CT on the consecutive
number of days that individuals are aﬀected by the common
cold.
For individual symptoms of the common cold, sig-
niﬁcant reductions in febrile symptoms (chills and fever)
were observed due to CT ingestion as well as a decreasing
trend in the incidence of other predominant symptoms, for
example, runny nose, sore throat, and joint pain. Riedel
and Maulik reported that the increase in body temperature
after lipopolysaccharide stimulation can be suppressed by
administering a reducing agent, and they suggested the
possibility that the increase in reduced GSH in response to
the reducing agent suppressed fever [23]. NAC is known
to show anti-inﬂammatory eﬀects via GSH [24]. Reduced
GSH is known to suppress the activation of NF-κB, which
is an inﬂammatory mediator at the time of rhinoviral
infection [21]. These ﬁndings suggest that the suppression
of individual symptoms of the common cold in the present
study may have been due to the anti-inﬂammatory eﬀect of
increased GSH caused by CT ingestion. In this trial, there
were some cases of observed symptoms but a lack of a6 Journal of Amino Acids
cold during the trial. Consequently, we performed a Pearson
correlationcoeﬃcientanalysisbetweentheincidenceofcolds
during the trial and each symptom. The symptoms of chill
(r = 0.694), fever (r = 0.663), and arthralgia (r = 0.610)
showed strong correlations with the incidence of colds. In
addition, the symptoms of cough (r = 0.467), runny nose
(r = 0.458), and headache (r = 0.451) showed moderate
correlations with the incidence of colds. These ﬁndings
suggest that the deﬁnition of colds used in the present trial
has a strong correlation with relatively severe symptoms.
In evaluating the safety of this study, we observed a
relatively high incidence of diarrhea in the CT group as an
adverse event. However, approximately the same incidence
of diarrhea was observed in the P group, and therefore this
eﬀect is unlikely to be an adverse reaction speciﬁc to CT
ingestion. In the present study, tablets were used in the
form of a test meal. These tablets contained nondigestible
substances, such as crystalline cellulose and dextrin, to
maintain their shape, and these substances may have aﬀected
the digestive system.
CT, which has been shown to reinforce GSH synthesis
and antibody production in mice following antigen stimula-
tion, was used in humans, and a signiﬁcant inhibitory eﬀect
on the common cold has been observed. In a clinical study in
humans, Miyagawa et al. reported that oral administration
of CT improves antibody production in the elderly, with
decreased immune function at the time of ﬂu vaccination
[25]. Moreover, Murakami et al. reported that CT ingestion
by long-distance runners before a training camp suppressed
the increase in blood neutrophil counts and the decrease in
lymphocytecountsobservedincontrolsubjectsaftertraining
[26]. Those results suggest that CT ingestion may improve
the immunosuppression induced by aging in the elderly and
by intense exercise in athletes. To determine whether this
common cold inhibitory eﬀect is due to the reinforcement
of GSH synthesis and antibody production by CT ingestion,
more detailed analyses are required using both animal and
human subjects. The results of the present exploratory trial
showed that CT is an eﬀective and safe drug as a food
ingredient to suppress the common cold, and we anticipate
its use as a drug or food ingredient for cold prevention and
symptom relief in the future.
5. Conclusion
A randomized, placebo-controlled 5-week trial indicated
that CT supplementation signiﬁcantly reduced the inci-
dences of colds and of fever symptoms, but had no apparent
eﬀect on the duration of colds. These results suggest that
CT supplementation may be useful for the prevention of the
common cold.
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